{"classes":[{"categories":[{"measurements":[{"comment":"True baseline sample were not available so post-treatment samples were compared with post-study surgical specimens which was not an accurate baseline measure.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"True baseline sample were not available so post-treatment samples were compared with post-study surgical specimens which was not an accurate baseline measure.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"-12.57","upperLimit":"100","value":"85.6"},{"comment":"Inhibition of tumor FAK was not included in Cohort 4, as per the protocol.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"percentage VS-6063 (defactinib)","dispersionType":"Full Range","groups":[{"description":"Defactinib 400 mg BID for 12 Days","id":"OG000","title":"Cohort 1"},{"description":"Defactinib 400 mg BID for 35 Days","id":"OG001","title":"Cohort 2"},{"description":"Defactinib 400 mg BID for 21 Days","id":"OG002","title":"Cohort 3"},{"description":"Defactinib 100 mg BID for 21 Days","id":"OG003","title":"Cohort 4"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Cohort 1, From Baseline to Day 12; Cohort 2, From Baseline to Day 35; Cohorts 3, From Baseline to Day 21; Cohorts 3, From Baseline to day 21 day.","title":"Percentage of pFAK Inhibition in Tumor Tissue","type":"PRIMARY","unitOfMeasure":"percentage of pFAK inhibition in a tumor"}